Yazdani Aryan M, Fattahi Mohammad Reza, Eftekhari Mohammad Hassan, Ahmadi Afsane, Soveid Mahmood, Zare Morteza, Mohsenpour Mohammad Ali
Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
J Diabetes Metab Disord. 2025 May 15;24(1):120. doi: 10.1007/s40200-025-01632-6. eCollection 2025 Jun.
Synbiotic supplements have been shown to affect type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD), however; results remain inconclusive. Thus, the present study was designed to investigate the potential effect of multi-strain synbiotic supplements on liver enzymes, insulin resistance, anthropometric indices, and inflammatory markers in overweight/obese patients with NAFLD and T2DM.
In a 12-week triple-blinded randomized controlled trial, 40 eligible overweight or obese adults with NAFLD and T2DM were randomly assigned to two groups to consume either synbiotic supplements or a placebo along a low-calorie diet. Participants were assessed for liver enzymes, anthropometric and glycemic indices, and lipid profiles before and after the study.
After the study period, using intention-to-treat approach 20 individuals were included in the final analysis for each group. The intervention group showed significant reductions in within group analysis for insulin levels, weight, and BMI ( < 0.05). AST was reduced in both intervention and control groups. However, no significant differences were found for between-group analyses. Additionally, changes in inflammatory markers, lipid profiles, and insulin resistance indices were not statistically significant.
In the present study, synbiotic supplements showed improvements in insulin levels, weight, BMI, and AST. However, in comparison to the control group no beneficial effects were observed. Further studies are recommended to draw more definitive conclusions.
已表明合生元补充剂会影响2型糖尿病(T2DM)和非酒精性脂肪性肝病(NAFLD),然而,结果仍无定论。因此,本研究旨在调查多菌株合生元补充剂对患有NAFLD和T2DM的超重/肥胖患者的肝酶、胰岛素抵抗、人体测量指标和炎症标志物的潜在影响。
在一项为期12周的三盲随机对照试验中,40名符合条件的患有NAFLD和T2DM的超重或肥胖成年人被随机分为两组,在低热量饮食的同时分别服用合生元补充剂或安慰剂。在研究前后对参与者进行肝酶、人体测量和血糖指标以及血脂谱评估。
在研究期结束后,采用意向性分析方法,每组有20名个体纳入最终分析。干预组在组内分析中胰岛素水平、体重和BMI显著降低(P<0.05)。干预组和对照组的AST均降低。然而,组间分析未发现显著差异。此外,炎症标志物、血脂谱和胰岛素抵抗指数的变化无统计学意义。
在本研究中,合生元补充剂在胰岛素水平、体重、BMI和AST方面有所改善。然而,与对照组相比,未观察到有益效果。建议进一步研究以得出更明确的结论。